

November 28, 2019

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051  <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001  <b>Company Code No. 524804</b>
---	---

Dear Sir,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

This is to inform you that Auro Vaccines LLC, 100% subsidiary of Aurobindo Pharma USA Inc., USA, which in turn is 100% subsidiary of the Company, has entered into a definitive agreement to acquire certain business assets from Profectus BioSciences Inc., USA., a clinical-stage vaccine development company.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as 'Annexure A'.

This is for your information and record.

Yours faithfully,  
**For AUROBINDO PHARMA LIMITED**

  
**B. Adi Reddy**  
**Company Secretary**

Enclosures: Annexure A



**AUROBINDO PHARMA LIMITED**

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

[www.aurobindo.com](http://www.aurobindo.com)

**AUROBINDO****Annexure A**

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) Name of the target entity, details in brief such as size, turnover etc.;	<b>i) Name of the Target :</b> Acquisition of certain R&D assets from 'Profectus BioSciences Inc'., USA (the "Target").  The Target is a clinical-stage vaccine development company in the design and development of preventive and therapeutic vaccines.
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length";	The Target is an independent company.  The promoter/ promoter group/ group companies of Aurobindo Pharma Limited have no interest in the Target so the acquisition would not fall within related party transaction(s).
c) Industry to which the entity being acquired belongs;	Pharmaceuticals – R & D.
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	<ul style="list-style-type: none"> <li>Acquisition provides access to - Proprietary &amp; Innovative technology platforms for Prophylactic use &amp; Therapeutic use along with Global R&amp;D center.</li> <li>Acquisition will lead to enhancement of R &amp; D capabilities and expertise in developing newer vaccines from basic discovery research into FDA-approved product.</li> </ul>
e) Brief details of any governmental or regulatory approvals required for the acquisition;	Closing of the transaction is subject to Government approvals & Third Party Consents.
f) Indicative time period for completion of the acquisition;	First Half of 2020.
g) Nature of consideration - whether cash consideration or share swap and details of the same	Cash Consideration
h) Cost of acquisition or the price at which the shares are acquired;	Only assets are acquired for an upfront cash consideration USD 11.29 million with potential earn outs on achieving certain milestones.
i) Percentage of shareholding / control acquired and / or number of shares acquired;	No control / shares were acquired.  The Company acquires certain business assets that are being used for R & D through Auro Vaccines LLC, 100% subsidiary of Aurobindo Pharma USA Inc., USA, which in turn is 100% subsidiary of Aurobindo Pharma Limited, India.
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	The acquisition is certain business assets from the Target.  We are acquiring R&D and product development assets that would develop products for commercialization by the Company.

**AUROBINDO PHARMA LIMITED**

(CIN : L24239TG1986PLC015190)

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off.: Plot No. 2, Maithrivi, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

[www.aurobindo.com](http://www.aurobindo.com)